Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Nat Med. 2009 Jun 14;15(7):808–813. doi: 10.1038/nm.1982

Figure 4. TSCM possess enhanced in vivo recall response and anti-tumor activity compared to TCM and TEM.

Figure 4

Pmel-1 naive CD8+ T cells were primed in vitro with splenocytes pulsed with 1 μM hgp10025–33, in conjunction with 10 ng ml−1 IL-2 with or without 7 μM TWS119. Five days after antigenic stimulation, TSCM, TCM or TEM were sorted based on the phenotype. Sublethally-irradiated WT mice received 5 × 104 pmel-1 TSCM, TCM or TEM in conjunction with a recombinant vaccinia virus encoding hgp100 and exogenous IL-2. a, Absolute numbers of adoptively transferred pmel-1 cells (identified by CD8+ thy1.1+ lymphocytes) in the spleens of treated animals. Data are represented as mean +/− SEM. b, Flow cytometry analysis for the expression of CD8 and thy1.1. c, Tumor treatment and survival of sublethally-irradiated WT mice bearing B16 tumors established for 10 days (n = 5 for all groups) receiving 4 × 104 pmel-1 TSCM, TCM or TEM in conjunction with a recombinant vaccinia virus encoding hgp100 and exogenous IL-2. Data are represented as mean +/− SEM. All data shown are representative of at least two independently performed experiments.